We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cancer Survival Not Impacted by Red Blood Cells Storage

By LabMedica International staff writers
Posted on 17 Oct 2013
Print article
Image: Blood Bank Refrigerator (Photo courtesy of Thermo Electron).
Image: Blood Bank Refrigerator (Photo courtesy of Thermo Electron).
The duration of storage of transfused red blood cells (RBC) has been associated with poor clinical outcomes and may influence cancer patients overall survival or recurrence.

The goal of RBC transfusion is to increase the delivery of oxygen to tissue in vulnerable patients and remains an essential component in the management of medically ill patients, but changes that occur during storage might impair oxygen delivery through a multitude of metabolic and physiologic changes that ensue.

Transfusion specialists at the Ottawa Hospital (ON, Canada) analyzed the data from 27,591 patients diagnosed with cancer between January 01, 2000 and December 31, 2005. There were 1,929 patients who had received RBC transfusions within one year from diagnosis. Transfused RBC units were categorized as "new'' if stored for less than 14 days, "intermediate'' if stored between 14 and 28 days and "old'' if stored for more than 28 days.

Overall survival was not associated with duration of storage of transfused RBC with a median survival of 1.2 years for new RBC units, 1.7 years for intermediate storage, and 1.1 years for older RBC units. The mean number of RBC transfusions was 3.42 with 55.5% of patients, receiving between one to two RBC units. Of those patients who received a RBC transfusion within one year from diagnosis, 56.8% were transfused within the first six months. Almost half of the patients requiring transfusion within the first year from diagnosis had either a gastrointestinal or lung malignancy.

Cancer recurrence, defined as recurrence of original malignancy or new metastatic disease, was significantly higher in patients who received a RBC transfusion than those who did not, but recurrence rates were not significantly influenced by the duration of storage of transfused RBC. The data from the study suggests that the duration of storage of transfused RBC has a negligible effect on overall survival (OS) of cancer patients. Not surprisingly, OS was influenced by the patient’s age, advanced stage, chemotherapy and radiation use, cancer-related surgery and cancer recurrence. Although receiving a RBC transfusion was associated with OS in univariate analysis, this was not evident when accounting for confounding variables.

The authors concluded their study highlights the inferior survival of cancer patients requiring RBC transfusions; however, there is no apparent influence of the duration of storage of transfused RBC units on OS or cancer recurrence. They concluded that current RBC transfusion policies that do not differentiate between duration of storage of RBC units are adequate for patients with underlying malignancy. The study was published on July 16, 2013, in the journal Public Library of Science ONE.

Related Links:

Ottawa Hospital


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.